The approval of disease-modifying therapies for early, symptomatic Alzheimer’s disease is raising hope for patients and caregivers. And promising new therapeutic and diagnostic capabilities are expected in the next five … Read More
Multistakeholder Consortium Unveils Systems-Level Roadmap to Transform Obesity Disease Management
Cross-stakeholder initiative addresses why 96% of adults with obesity don’t receive medical care, a $1.4 trillion healthcare gap Boston, June 25, 2025—The Center for Biomedical System Design (CBSD) program at … Read More
“Hope for some and gaps for many” in Therapy Pipeline for Pediatric Onset Rare Diseases
New Study Projects Future of Approvals, Patients Treated, Costs, and Gaps in Treatment Options Boston, May 14, 2025—New research in Journal of Managed Care + Specialty Pharmacy (JMCP) provides insights into the future … Read More
Journal of Managed Care + Specialty Pharmacy: 10-year projection of pediatric onset rare disease therapy approvals, treated patients, and list price revenues
New research in Journal of Managed Care + Specialty Pharmacy (JMCP) provides insights into the future landscape of treatments for rare diseases that present in childhood, offering a balanced picture … Read More
NEWDIGS explores System Dynamics Modeling to address barriers to access of effective therapies
System barriers to the appropriate, timely, and equitable use of biomedical innovations have led to slow and inconsistent adoption, limiting their full potential impact on patient outcomes. For 16 years … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Nature Reviews Drug Discovery: Clinical development success rates for durable cell and gene therapies
Our article compares the clinical development success rates of durable cell and gene therapies (dCGTs) from 1988 to 2023 with BIO and IQVIA’s published benchmarks for all therapeutic modalities. As … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Health Affairs Forefront: Bringing Systems Thinking to Drug Value Assessment
Drug value assessments generally fail to account for the complexities of health care systems and thus can misinform price negotiations and lead to overly restrictive access policies. Our [new article … Read More
Implementation Brief: Implementing an innovative contract
The contract is signed—now what? Next, stakeholders must prepare to implement the innovative contract. This brief offers a checklist of potential considerations for executing the agreement, including aligning stakeholders and … Read More